KR20090047501A - 화학요법에 의해 유발된 신경병증의 치료에 기여하는 방법 및 약학 제제 - Google Patents

화학요법에 의해 유발된 신경병증의 치료에 기여하는 방법 및 약학 제제 Download PDF

Info

Publication number
KR20090047501A
KR20090047501A KR1020097004261A KR20097004261A KR20090047501A KR 20090047501 A KR20090047501 A KR 20090047501A KR 1020097004261 A KR1020097004261 A KR 1020097004261A KR 20097004261 A KR20097004261 A KR 20097004261A KR 20090047501 A KR20090047501 A KR 20090047501A
Authority
KR
South Korea
Prior art keywords
cisplatin
pharmaceutical formulation
reteprinim
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020097004261A
Other languages
English (en)
Korean (ko)
Inventor
구루 레디
돌라 미레조브스키
루이기 레나즈
Original Assignee
스펙트럼 파마슈티컬즈 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스펙트럼 파마슈티컬즈 인크 filed Critical 스펙트럼 파마슈티컬즈 인크
Publication of KR20090047501A publication Critical patent/KR20090047501A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097004261A 2006-08-01 2007-08-01 화학요법에 의해 유발된 신경병증의 치료에 기여하는 방법 및 약학 제제 Withdrawn KR20090047501A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82108206P 2006-08-01 2006-08-01
US60/821,082 2006-08-01

Publications (1)

Publication Number Publication Date
KR20090047501A true KR20090047501A (ko) 2009-05-12

Family

ID=38744846

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097004261A Withdrawn KR20090047501A (ko) 2006-08-01 2007-08-01 화학요법에 의해 유발된 신경병증의 치료에 기여하는 방법 및 약학 제제

Country Status (12)

Country Link
EP (1) EP2046335A2 (enExample)
JP (1) JP2009545619A (enExample)
KR (1) KR20090047501A (enExample)
CN (1) CN101657199A (enExample)
BR (1) BRPI0715504A2 (enExample)
CA (1) CA2659477A1 (enExample)
IL (1) IL196824A0 (enExample)
MX (1) MX2009001116A (enExample)
NO (1) NO20090279L (enExample)
RU (1) RU2009107123A (enExample)
WO (1) WO2008017000A2 (enExample)
ZA (1) ZA200900728B (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004448A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions

Also Published As

Publication number Publication date
BRPI0715504A2 (pt) 2014-05-06
EP2046335A2 (en) 2009-04-15
IL196824A0 (en) 2009-11-18
RU2009107123A (ru) 2010-09-10
MX2009001116A (es) 2009-02-10
CA2659477A1 (en) 2008-02-07
WO2008017000A3 (en) 2008-03-20
WO2008017000A8 (en) 2009-04-30
ZA200900728B (en) 2010-03-31
CN101657199A (zh) 2010-02-24
NO20090279L (no) 2009-02-26
JP2009545619A (ja) 2009-12-24
WO2008017000A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US20090018142A9 (en) Use of phosphatases to treat tumors overexpressing N-CoR
CA2641308A1 (en) Use of phosphatases to treat tumors overexpressing n-cor
Takenami et al. Neurotoxicity of intrathecally administered bupivacaine involves the posterior roots/posterior white matter and is milder than lidocaine in rats
US12201608B2 (en) Methods for treating Parkinson's disease by administering resiniferatoxin
CA2718472A1 (en) Use of phosphatases to treat neuroblastomas and medulloblastomas
KR102462638B1 (ko) 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
EP4275749A2 (en) Treating neuropathic pain associated with chemotherapy-induced peripheral neuropathy
EP3258930B1 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
US12357665B2 (en) Pharmaceutical compositions and uses thereof in treating muscle atrophy
Chiorazzi et al. Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models
Hoskin et al. The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat
CN121059573A (zh) 通过paris的法尼基化预防或治疗帕金森症的方法
US9328060B2 (en) J-series prostaglandin-ethanolamides as novel therapeutics
Cole et al. Pre-treatment of adult rats with high doses of erythropoietin induces caspase-9 but prevents light-induced retinal injury
EP0535719A2 (en) Treatment of hemorrhoids with artemisinin and derivates
CN101657199A (zh) 帮助治疗化学疗法诱导的神经病的方法和药物制剂
JP7847357B2 (ja) ミトコンドリアを標的とするイソケタール／イソレブグランジンスカベンジャー
US6821997B1 (en) Therapeutic and prophylactic treatment of aging and disorders of aging in humans
DE602004009098T2 (de) Cci-779 zur behandlung von mantelzelllymphom
JP2019531296A (ja) 眼疾患の処置方法
US12252522B2 (en) Myokines for treating cell proliferative and metabolic diseases and disorders
US11446264B2 (en) Memory manipulation via modification of protein kinase C zeta activity
Porter et al. Effect of low dose intra-arterial reserpine on vascular wall norepinephrine content
CN120570874A (zh) 高牛磺酸在抑制脊髓损伤后巨噬细胞衰老中的用途
HK40100168A (zh) 治疗与化学疗法诱发的周围神经病变相关的疼痛

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid